These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15591512)

  • 1. Cost effectiveness of a new strategy to identify HNPCC patients.
    Kievit W; de Bruin JH; Adang EM; Severens JL; Kleibeuker JH; Sijmons RH; Ruers TJ; Nagengast FM; Vasen HF; van Krieken JH; Ligtenberg MJ; Hoogerbrugge N
    Gut; 2005 Jan; 54(1):97-102. PubMed ID: 15591512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness.
    Reyes CM; Allen BA; Terdiman JP; Wilson LS
    Cancer; 2002 Nov; 95(9):1848-56. PubMed ID: 12404277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability].
    de Bruin JH; Kievit W; Ligtenberg MJ; Nagengast FM; Adang EM; Ruers TJ; Kleibeuker JH; Sijmons RH; van Krieken JH; Hoogerbrugge N
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1792-8. PubMed ID: 16121665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the detection of hereditary non-polyposis colorectal cancer: an update.
    De Bruin JH; Ligtenberg MJ; Nagengast FM; Adang EM; Van Krieken JH; Hoogerbrugge N
    Scand J Gastroenterol Suppl; 2006; (243):146-52. PubMed ID: 16782634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer.
    Ramsey SD; Clarke L; Etzioni R; Higashi M; Berry K; Urban N
    Ann Intern Med; 2001 Oct; 135(8 Pt 1):577-88. PubMed ID: 11601929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.
    Domingo E; Laiho P; Ollikainen M; Pinto M; Wang L; French AJ; Westra J; Frebourg T; Espín E; Armengol M; Hamelin R; Yamamoto H; Hofstra RM; Seruca R; Lindblom A; Peltomäki P; Thibodeau SN; Aaltonen LA; Schwartz S
    J Med Genet; 2004 Sep; 41(9):664-8. PubMed ID: 15342696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective assessment of microsatellite instability in gastrointestinal neoplasia in Ashkenazi and non-Ashkenazi Jews.
    Strul H; Liberman E; Kariv R; Gartner M; Kazanov D; Keidar A; Carmeli Y; Degani Y; Halpern Z; Arber N
    J Med; 2003; 34(1-6):139-48. PubMed ID: 17682319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers.
    Vasen HF; van Ballegooijen M; Buskens E; Kleibeuker JK; Taal BG; Griffioen G; Nagengast FM; Menko FH; Meera Khan P
    Cancer; 1998 May; 82(9):1632-7. PubMed ID: 9576281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma.
    Breheny N; Geelhoed E; Goldblatt J; Ee H; O'Leary P
    Community Genet; 2006; 9(2):98-106. PubMed ID: 16612060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer.
    Olsen KR; Bojesen SE; Gerdes AM; Lindorff-Larsen K; Bernstein IT
    Int J Technol Assess Health Care; 2007; 23(1):89-95. PubMed ID: 17234021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
    Johnson V; Lipton LR; Cummings C; Eftekhar Sadat AT; Izatt L; Hodgson SV; Talbot IC; Thomas HJ; Silver AJ; Tomlinson IP
    J Med Genet; 2005 Oct; 42(10):756-62. PubMed ID: 15788729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis.
    Kievit W; de Bruin JH; Adang EM; Ligtenberg MJ; Nagengast FM; van Krieken JH; Hoogerbrugge N
    Clin Genet; 2004 Apr; 65(4):308-16. PubMed ID: 15025724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular screening of potential HNPCC patients using a multiplex microsatellite PCR system.
    Sutter C; Gebert J; Bischoff P; Herfarth C; von Knebel Doeberitz M
    Mol Cell Probes; 1999 Apr; 13(2):157-65. PubMed ID: 10208807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: Detection and management of hereditary non-polyposis colorectal cancer (Lynch syndrome).
    Ramsoekh D; Van Leerdam ME; Wagner A; Kuipers EJ
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():101-11. PubMed ID: 18081654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of hereditary non-polyposis colon cancer (HNPCC)].
    Guimbaud R; Selves J
    J Chir (Paris); 2003 Dec; 140(6):317-23. PubMed ID: 14978439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to identification of HNPCC suspected patients in Slovak population.
    Fridrichová I; Ilencíková D; Friedl W; Hlavcák P; Skorvaga M; Krizan P; Pálaj J; Pirsel M; Farkasová E; Bartosová Z
    Neoplasma; 2000; 47(4):219-26. PubMed ID: 11043825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening.
    Julié C; Trésallet C; Brouquet A; Vallot C; Zimmermann U; Mitry E; Radvanyi F; Rouleau E; Lidereau R; Coulet F; Olschwang S; Frébourg T; Rougier P; Nordlinger B; Laurent-Puig P; Penna C; Boileau C; Franc B; Muti C; Hofmann-Radvanyi H
    Am J Gastroenterol; 2008 Nov; 103(11):2825-35; quiz 2836. PubMed ID: 18759827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumour examination to detect hereditary colorectal cancer].
    Hoogerbrugge N; Hermens RP; Nagengast F; Overbeek L; van Krieken HJ; Ligtenberg M
    Ned Tijdschr Geneeskd; 2012; 156(42):A4982. PubMed ID: 23075775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
    Ladabaum U; Wang G; Terdiman J; Blanco A; Kuppermann M; Boland CR; Ford J; Elkin E; Phillips KA
    Ann Intern Med; 2011 Jul; 155(2):69-79. PubMed ID: 21768580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.